Wealthspire Advisors LLC Has $946,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Wealthspire Advisors LLC raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,794 shares of the company’s stock after buying an additional 114 shares during the period. Wealthspire Advisors LLC’s holdings in Zoetis were worth $946,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ZTS. Wellington Management Group LLP grew its stake in Zoetis by 2.5% in the third quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock valued at $2,147,730,000 after purchasing an additional 297,044 shares in the last quarter. Northern Trust Corp increased its holdings in Zoetis by 3.3% in the third quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock worth $1,068,804,000 after buying an additional 196,771 shares during the last quarter. Royal Bank of Canada raised its position in Zoetis by 3.1% during the third quarter. Royal Bank of Canada now owns 3,026,518 shares of the company’s stock valued at $526,553,000 after acquiring an additional 91,713 shares in the last quarter. Blair William & Co. IL lifted its stake in Zoetis by 1.4% in the third quarter. Blair William & Co. IL now owns 2,428,509 shares of the company’s stock valued at $422,512,000 after acquiring an additional 32,918 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Zoetis by 0.5% in the third quarter. Principal Financial Group Inc. now owns 2,126,090 shares of the company’s stock valued at $369,736,000 after acquiring an additional 10,153 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 2,209 shares of company stock worth $371,293. 0.16% of the stock is currently owned by company insiders.

Zoetis Stock Performance

NYSE ZTS traded up $1.16 during trading on Friday, hitting $169.29. The company’s stock had a trading volume of 86,488 shares, compared to its average volume of 3,149,814. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The firm has a market cap of $77.25 billion, a P/E ratio of 32.39, a price-to-earnings-growth ratio of 2.57 and a beta of 0.86. The firm has a 50 day moving average price of $166.94 and a 200 day moving average price of $178.83. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. The business had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. Zoetis’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.31 earnings per share. Equities research analysts forecast that Zoetis Inc. will post 5.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

ZTS has been the topic of a number of recent research reports. Piper Sandler restated an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Stifel Nicolaus reduced their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. HSBC decreased their price target on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday. Barclays cut their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Finally, StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $211.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.